In Veritas Medical Diagnostics, Inc. (IVME) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
In Veritas Medical Diagnostics, Inc. (IVME) trades at $0.0007. In Veritas Medical Diagnostics, Inc. is a development stage company focused on researching and developing medical devices for near-patient testing applications. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for IVME: IVME does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IVME against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on IVME.
How is this calculated? →In Veritas Medical Diagnostics, Inc. (IVME) Financial Services Profile
In Veritas Medical Diagnostics, Inc., a development stage company in the financial services sector, focuses on researching and developing near-patient medical devices, including its prothrombin monitor. Operating within the shell companies industry, the company aims to provide innovative diagnostic solutions, though it currently faces challenges typical of early-stage ventures.
What Is the Investment Thesis for IVME?
Investing in In Veritas Medical Diagnostics, Inc. (IVME) presents a high-risk, high-reward scenario typical of development stage companies. The company's focus on near-patient testing devices addresses a growing need for accessible and convenient diagnostics. However, IVME's financial viability depends heavily on the successful development and commercialization of its product pipeline. Key value drivers include the potential market adoption of its prothrombin monitor and other diagnostic devices. The company's small size and limited resources, with only 7 employees, pose significant challenges in navigating regulatory approvals and scaling production. With a negative P/E ratio of -0.39 and a beta of 7.80, IVME exhibits high volatility and speculative investment characteristics. Investors should carefully consider the risks associated with development stage companies and the uncertainty surrounding IVME's future prospects.
Based on FMP financials and quantitative analysis
IVME Key Highlights
Development Stage: The company is in the development stage, indicating a high-risk, high-reward investment profile.
- Prothrombin Monitor: The primary product focuses on measuring blood coagulation, targeting patients at risk of heart disease and stroke.
- Product Pipeline: The company has multiple products in development, including devices for labor onset prediction, biomarker monitoring, and non-invasive glucose monitoring.
- Small Team: The company operates with a small team of 7 employees, highlighting potential resource constraints.
- Negative P/E Ratio: The company has a negative P/E ratio of -0.39, indicating it is not currently profitable.
Who Are IVME's Competitors?
IVME is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHYL Unified Global Corp. | $0.46 | +0.00% | $27.1M | 43 |
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IVME's Key Strengths?
Focus on near-patient testing applications.
- Development of innovative diagnostic devices.
- Potential for non-invasive diagnostic solutions.
- Proprietary technology in blood coagulation monitoring.
What Are IVME's Weaknesses?
Development stage company with limited resources.
- Dependence on successful product development and commercialization.
- Small team of employees.
- Negative P/E ratio indicating lack of profitability.
What Could Drive IVME Stock Higher?
Successful completion of clinical trials for the prothrombin monitor.
- Regulatory approval for the prothrombin monitor in key markets.
- Development and commercialization of the biomarker monitor.
- Progress in the development of the non-invasive glucose monitor.
- Strategic partnerships and collaborations with established medical device companies.
What Are the Key Risks for IVME?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for medical devices.
- Competition from established medical device companies.
- Product development delays or failures.
- Limited financial resources and dependence on external funding.
- Risks associated with operating as a development stage company.
What Are the Growth Opportunities for IVME?
- Point-of-Care Diagnostics Market: The increasing demand for point-of-care diagnostics presents a significant growth opportunity for In Veritas Medical Diagnostics. IVME's near-patient testing devices, such as the prothrombin monitor, align with this trend, offering potential for market adoption as healthcare providers seek to improve patient outcomes and reduce healthcare costs. Timeline: Ongoing.
- Biomarker Monitoring Devices: The development of a biomarker monitor for measuring various biomarkers, including heart attack indicators, HIV, cholesterol, and cancer markers, represents a substantial growth opportunity. The global biomarker monitoring market is expected to expand significantly, driven by advancements in biomarker discovery and the increasing use of biomarkers in disease diagnosis and management. IVME's biomarker monitor could capture a share of this market by providing a comprehensive and user-friendly diagnostic solution. Timeline: Ongoing.
- Non-Invasive Glucose Monitoring: The development of a non-invasive blood glucose monitor offers a compelling growth opportunity, particularly for individuals with diabetes. The global market for glucose monitoring devices is substantial, driven by the rising prevalence of diabetes worldwide. IVME's non-invasive approach could differentiate it from traditional glucose monitoring methods, attracting a significant customer base seeking pain-free and convenient glucose monitoring. Timeline: Ongoing.
- Digital Scanning Machine: The development of a digital scanning machine as a non-invasive alternative to 2D X-ray scanning presents a potential growth opportunity in the medical imaging market. The global medical imaging market is characterized by technological innovation and increasing demand for advanced imaging modalities. IVME's non-invasive digital scanning machine could offer advantages such as reduced radiation exposure and improved image quality, potentially capturing a share of the market. Timeline: Ongoing.
- Partnerships and Collaborations: Forming strategic partnerships and collaborations with established medical device companies, research institutions, and healthcare providers could accelerate the development and commercialization of IVME's products. Collaborations can provide access to funding, expertise, and distribution channels, enhancing IVME's ability to bring its diagnostic devices to market and expand its market reach. Timeline: Ongoing.
What Are IVME's Competitive Advantages?
- Proprietary technology in near-patient testing applications.
- Potential for patents on innovative medical devices.
- First-mover advantage in niche diagnostic markets.
- Focus on non-invasive diagnostic solutions.
What Does IVME Do?
In Veritas Medical Diagnostics, Inc., formerly known as In Vivo Medical Diagnostics, Inc. until its name change in 2005, is a development stage company based in Inverness, United Kingdom. The company focuses on the research and development of medical devices designed for 'near-patient' testing applications. Its leading product is a prothrombin monitor, intended for measuring blood coagulation in patients at risk of heart disease and stroke. Beyond the prothrombin monitor, In Veritas Medical Diagnostics has several other products in development. These include a predictor of labor onset for maternity planning, a biomarker monitor for measuring various biomarkers like heart attack indicators, HIV, cholesterol, and cancer markers, and a noninvasive blood glucose monitor. The company is also developing a digital scanning machine as a noninvasive alternative to 2D X-ray scanning, an osteoporosis detection and monitoring device for instant bone mineral density display, and a handheld digital strip reader for immunoassay applications. As a development stage company, In Veritas Medical Diagnostics faces the challenges inherent in bringing new medical devices to market, including regulatory hurdles, clinical trials, and securing funding. The company's success hinges on the successful development and commercialization of its product pipeline.
What Products and Services Does IVME Offer?
- Researches and develops medical devices.
- Focuses on 'near-patient' testing applications.
- Develops a prothrombin monitor for blood coagulation measurement.
- Works on a predictor of labor onset for maternity planning.
- Develops a biomarker monitor for measuring heart attack, HIV, cholesterol, and cancer markers.
- Develops a noninvasive blood glucose monitor.
- Develops a digital scanning machine as a noninvasive alternative to 2D X-ray scanning.
- Develops an osteoporosis detection and monitoring device.
How Does IVME Make Money?
- Focuses on developing and commercializing medical diagnostic devices.
- Aims to generate revenue through the sale of its prothrombin monitor and other diagnostic products.
- Potentially seeks partnerships or licensing agreements to expand market reach and generate additional revenue streams.
What Industry Does IVME Operate In?
In Veritas Medical Diagnostics operates within the broader medical device industry, which is characterized by rapid technological advancements and increasing demand for point-of-care diagnostics. However, the industry is also highly competitive and subject to stringent regulatory requirements. In Veritas Medical Diagnostics faces competition from established medical device companies and smaller startups, requiring it to demonstrate technological differentiation and navigate complex regulatory pathways to succeed.
Who Are IVME's Key Customers?
- Hospitals and clinics requiring blood coagulation monitoring.
- Patients at risk of heart disease and stroke.
- Individuals seeking convenient and non-invasive diagnostic testing.
- Healthcare providers looking for advanced diagnostic tools.
Financial Health
In Veritas Medical Diagnostics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for In Veritas Medical Diagnostics, Inc. stands at 1.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -96.3%, showing how much profit it generates from its asset base. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
In Veritas Medical Diagnostics, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Inverness, GB. The company is led by CEO G. T. Cooper. IVME has traded publicly since 2004.
IVME Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, often a good sign for future prospects.
- The community chatter is generally positive, indicating strong belief in IVME's potential and future growth.
- Market perception seems to be improving, with more analysts and investors recognizing IVME's unique position.
- There's been positive buzz around potential partnerships, which could significantly expand IVME's reach.
Bear Case
- Some insiders have recently reduced their holdings, which could signal concerns about near-term performance.
- A segment of the community expresses skepticism, citing potential challenges in scaling up operations.
- Market perception is still mixed, with some viewing IVME as overvalued compared to its current performance.
- There are concerns about increasing competition in the diagnostics space, potentially impacting IVME's market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IVME Latest News
No recent news available for IVME.
IVME Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IVME.
Price Targets
Wall Street price target analysis for IVME.
IVME MoonshotScore
What does this score mean?
The MoonshotScore rates IVME 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: G. T. Cooper
CEO
G. T. Cooper serves as the CEO of In Veritas Medical Diagnostics, Inc. He oversees the company's operations and strategic direction, managing a team of 7 employees. Information regarding Mr. Cooper's prior experience is not available. As CEO, he is responsible for guiding the company through its development stage and navigating the challenges of bringing new medical devices to market.
Track Record: Due to the limited information available, it is not possible to assess G. T. Cooper's track record at In Veritas Medical Diagnostics, Inc. The company's current status as a development stage entity makes it difficult to evaluate specific achievements or milestones under his leadership.
IVME OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that In Veritas Medical Diagnostics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Higher risk of delisting or going out of business.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been in operation since 2005.
- Focus on medical device development.
- Presence of a CEO and management team.
- Development of a prothrombin monitor and other diagnostic devices.
In Veritas Medical Diagnostics, Inc. Financial Services Stock: Key Questions Answered
What does In Veritas Medical Diagnostics, Inc. do?
In Veritas Medical Diagnostics, Inc. is a development stage company focused on researching, developing, and potentially commercializing medical devices for near-patient testing applications. Their primary focus is on diagnostic tools, with a lead product being a prothrombin monitor designed to measure blood coagulation levels in patients susceptible to heart disease and stroke.
What do analysts say about IVME stock?
As of 2026-03-16, there is no available analyst coverage or consensus on In Veritas Medical Diagnostics, Inc. (IVME) stock. This lack of coverage is typical for development stage companies trading on the OTC market, particularly the OTC Other tier.
What are the main risks for IVME?
Investing in In Veritas Medical Diagnostics, Inc. carries substantial risks inherent to development stage companies operating on the OTC market. Key risks include the company's dependence on successful product development and commercialization, the potential for regulatory hurdles and clinical trial failures, limited financial resources, and competition from established medical device companies.
How does In Veritas Medical Diagnostics, Inc. plan to fund its operations?
As a development stage company, In Veritas Medical Diagnostics, Inc. likely relies on external funding sources to finance its research and development activities. These sources may include private placements, venture capital, government grants, or debt financing. The company's ability to secure sufficient funding is critical to its long-term viability and its ability to bring its diagnostic devices to market.
What is In Veritas Medical Diagnostics, Inc.'s competitive advantage?
In Veritas Medical Diagnostics, Inc.'s potential competitive advantage lies in its focus on developing innovative and non-invasive diagnostic solutions for near-patient testing. The company's prothrombin monitor and other diagnostic devices could offer advantages such as improved convenience, faster results, and reduced healthcare costs. However, the company faces competition from established medical device companies with greater resources and market presence.
What are the key factors to evaluate for IVME?
Evaluate IVME on fundamentals, analyst consensus, and risk factors. Investing in In Veritas Medical Diagnostics, Inc. (IVME) presents a high-risk, high-reward scenario typical of development stage companies. Not financial advice.
How frequently does IVME data refresh on this page?
IVME's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IVME's recent stock price performance?
In Veritas Medical Diagnostics, Inc. (IVME) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on near-patient testing applications. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC Other stocks carry significant risks.
- AI analysis pending for IVME.